HAEMONETICS CORP (HAE) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, HAEMONETICS CORP's filing signal continuing positive.

Haemonetics Corporation is a global medical technology company focused on improving healthcare quality and efficiency through innovative solutions. The company operates across three primary segments: Plasma, Blood Center, and Hospital. Its Plasma segment provides automated collection systems and donor management software for plasma centers, crucial for pharmaceutical manufacturing. The Blood Center segment offers devices for collecting and processing blood components for transfusions, though it recently divested its Whole Blood product line. The Hospital segment is divided into Interventional Technologies (Vascular Closure, Sensor-Guided Technologies, Esophageal Protection) and Blood Management Technologies (Hemostasis Management, Cell Salvage, Transfusion Management), serving critical care and surgical needs. Haemonetics markets its products in approximately 95 countries, with its ten largest customers accounting for about 42% of its net revenues in fiscal year 2025.

Revenue is primarily driven by sales of plasma collection devices and disposables, blood collection and processing devices, and a range of hospital technologies including vascular closure, sensor-guided technologies, and blood management solutions. The Hospital segment, particularly Interventional Technologies and Blood Management Technologies, is identified as having the greatest growth potential.